Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Combination of Antidepressant Medications From Treatment Initiation for Major Depressive Disorder: A Double-Blind Randomized Study

Abstract

OBJECTIVE: Various classes of antidepressant medications generally induce remission of major depressive disorder in only about one-third of patients. In a previous study using mirtazapine or paroxetine alone or in combination from treatment initiation, the rate of patients who remitted within a 6-week period was twice that of patients using either drug alone. In this double-blind study, the authors sought to produce evidence for the superiority of different combinations of antidepressant drugs from treatment initiation. METHOD: Patients (N=105) meeting DSM-IV criteria for major depressive disorder were randomly assigned to receive, from treatment initiation, either fluoxetine monotherapy (20 mg/day) or mirtazapine (30 mg/day) in combination with fluoxetine (20 mg/day), venlafaxine (225 mg/day titrated in 14 days), or bupropion (150 mg/day) for 6 weeks. The primary outcome measure was the Hamilton Depression Rating Scale (HAM-D) score. RESULTS: The overall dropout rate was 15%, without notable differences among the four groups. Compared with fluoxetine monotherapy, all three combination groups had significantly greater improvements on the HAM-D. Remission rates (defined as a HAM-D score of 7 or less) were 25% for fluoxetine, 52% for mirtazapine plus fluoxetine, 58% for mirtazapine plus venlafaxine, and 46% for mirtazapine plus bupropion. Among patients who had a marked response, double-blind discontinuation of one agent produced a relapse in about 40% of cases. CONCLUSIONS: The combination treatments were as well tolerated as fluoxetine monotherapy and more clinically effective. The study results, which add to a growing body of evidence, suggest that use of antidepressant combinations from treatment initiation may double the likelihood of remission compared with use of a single medication.

Overview

Integrity signals

Registry

Crossref · 10.1176/appi.ajp.2009.09020186

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 32 references

Research works printed but not linked: 5

  1. First MB, 1994, Structured Clinical Interview for DSM-IV Axis I Disorders (SCID)
  2. Aldosary F, 2007, American College of Neuropsychopharmacology, 46th annual meeting, General Program, 254
  3. Thase ME, 2002, Psychopharmacol Bull, 36, 24
  4. Fava M, 2000, J Clin Psychiatry, 61, 37
  5. Wahlbeck K, 2000, Cochrane Database Syst Rev, 2, CD000059

Cited by

See all 322

Metadata

Authors
Blier, P., Ward, H. E., Tremblay, P., Laberge, L., Hébert, C., & Bergeron, R.
Affiliations
University of Ottawa (CA)
Venue
American Journal of Psychiatry
Published
2010-03-01
Volume
167
Issue
3
Pages
281-288
ISSN
  • 0002-953X (ISSN-L)
  • 1535-7228
OpenAlex
W2151590183
Cited by
316
References
32
Citations by year
2026: 6 · 2025: 5 · 2024: 9 · 2023: 7 · 2022: 15 · 2021: 27 · 2020: 14 · 2019: 12 · 2018: 11 · 2017: 8 · 2016: 24 · 2015: 28 · 2014: 17 · 2013: 34 · 2012: 32
FWCI
24.19
Type
journal article
Language
en
Open access
closed
Locations
  • American Journal of Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
  • Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
Keywords
major depressive disorder, antidepressant combination therapy, mirtazapine, fluoxetine, venlafaxine, bupropion, remission, treatment initiation, relapse after treatment discontinuation, antidepressant efficacy, tolerability
MeSH terms
Venlafaxine Hydrochloride, Mirtazapine, Adult, Antidepressive Agents, Cyclohexanols, Major Depressive Disorder, Double-Blind Method, Drug Therapy, Combination, Female, Fluoxetine, Humans, Male, Mianserin, Middle Aged, Personality Inventory, Psychometrics, Bupropion, Secondary Prevention

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Combination of Antidepressant Medications From Treatment Initiation for Major Depressive Disorder: A Double-Blind Randomized Study. https://app.cochat.ai/papers/10.1176/appi.ajp.2009.09020186
The paper
Blier, P., Ward, H. E., Tremblay, P., Laberge, L., Hébert, C., & Bergeron, R. (2010). Combination of Antidepressant Medications From Treatment Initiation for Major Depressive Disorder: A Double-Blind Randomized Study. American Journal of Psychiatry. https://doi.org/10.1176/appi.ajp.2009.09020186

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.